GlassScriptPhysician profile
Jason Stevens
NPI 1568921468
$14,600.71
in general payments reported to CMS, 2019-2025
26 companies · $6,006 in 2025
The $6,006 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $1,632 · 2024: $6,793 · 2025: $6,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,913.41 |
| Education | $518.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,735.84 | 2023-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,938.19 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,449.64 | 2023-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $1,393.16 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $1,354.79 | 2023-2025 | Tremfya |
| Genzyme Corporation | $1,113.65 | 2023-2025 | |
| Leo Pharma INC. | $1,048.25 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $542.63 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $405.30 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $390.72 | 2023-2025 | Zoryve |
| Amgen INC. | $376.56 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $362.45 | 2024-2025 | |
| Lilly USA, LLC | $288.69 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $233.05 | 2025 | Aklief, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $211.63 | 2023-2024 | Siliq, Duobrii, Altreno |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $191.41 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $186.69 | 2025 | |
| Organon LLC | $152.50 | 2025 | Vtama |
| Journey Medical Corporation | $67.01 | 2025 | |
| Glaxosmithkline, LLC. | $30.73 | 2024 | Shingrix |
| Botanix Sb INC | $29.62 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2023 | Spevigo |
| Krystal Biotech INC | $21.60 | 2025 | Vyjuvek |
| Almirall LLC | $21.36 | 2025 | Seysara |
| Verrica Pharmaceuticals INC. | $18.91 | 2024 | Ycanth |
| Biofrontera INC. | $8.62 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.